A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Papayannidis, C
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. [electronic resource] - Blood cancer journal Sep 2015 - e350 p. digital
Publication Type: Clinical Trial, Phase I; Letter; Research Support, Non-U.S. Gov't
2044-5385
10.1038/bcj.2015.80 doi
Adolescent
Adult
Antineoplastic Agents--pharmacokinetics
Female
High-Throughput Nucleotide Sequencing
Humans
Male
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy
Receptor, Notch1--genetics
Tetrahydronaphthalenes--therapeutic use
Valine--analogs & derivatives
Young Adult
A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. [electronic resource] - Blood cancer journal Sep 2015 - e350 p. digital
Publication Type: Clinical Trial, Phase I; Letter; Research Support, Non-U.S. Gov't
2044-5385
10.1038/bcj.2015.80 doi
Adolescent
Adult
Antineoplastic Agents--pharmacokinetics
Female
High-Throughput Nucleotide Sequencing
Humans
Male
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy
Receptor, Notch1--genetics
Tetrahydronaphthalenes--therapeutic use
Valine--analogs & derivatives
Young Adult